Boston Scientific Derivative, gross, assets increased by 37.4% to $125.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 33.5%, from $188.00M to $125.00M. Over 4 years (FY 2020 to FY 2024), Derivative, gross, assets shows an upward trend with a 12.2% CAGR.
An increase indicates that the company's hedging positions are gaining value, potentially offsetting risks in the underlying physical assets.
This represents the aggregate fair market value of all derivative financial instruments that are in an asset position at...
Highly dependent on market conditions; peers in the energy sector often show significant fluctuations based on commodity price cycles.
other_derivative_fair_value_of_derivative_asset| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $322.00M | $369.00M | $394.00M | $422.00M | $538.00M | $652.00M | $381.00M | $319.00M | $388.00M | $396.00M | $266.00M | $302.00M | $313.00M | $188.00M | $384.00M | $232.00M | $91.00M | $125.00M |
| QoQ Change | — | +14.6% | +6.8% | +7.1% | +27.5% | +21.2% | -41.6% | -16.3% | +21.6% | +2.1% | -32.8% | +13.5% | +3.6% | -39.9% | +104.3% | -39.6% | -60.8% | +37.4% |
| YoY Change | — | — | — | — | +67.1% | +76.7% | -3.3% | -24.4% | -27.9% | -39.3% | -30.2% | -5.3% | -19.3% | -52.5% | +44.4% | -23.2% | -70.9% | -33.5% |